Table 3 Cost effectiveness outputs comparing KP and KP + AMETHIST (All costs/Disability adjusted life years (DALYs) are discounted at 3% per year, over a 50 year time horizon in the context of 10 million adults)
Continuation of KP from 2024 onwards | KP + AMETHIST from 2024 onwards | |
|---|---|---|
Costs/DALYs are given per year, over a 50 year time Horizon | Mean across runs (95% CI) | Mean across runs (95% CI) |
Overall costs in US$ millions assuming $132/year for KP and $155/year AMETHIST (based on costs collected in AMETHIST) | 156 (153, 160) | 154 (151, 158) |
Difference in overall costs | −1.9 (−2.6, −1.1) | |
ART costs | 40 (38, 42) | 38 (37, 40) |
Difference in ART costs | −1.3 (−1.6, −1.1) | |
Testing costs | 17 (16, 18) | 17 (16, 19) |
Difference in testing costs | 0.1 (0.0, 0.3) | |
Other programme costs | 99 (97, 102) | 99 (96, 101) |
Difference in other programme costs | −0.7 (−1.1, −0.2) | |
Testing costs amongst SW | 0.02 (0.02, 0.02) | 0.14 (0.12, 0.17) |
Difference in testing costs amongst SW | 0.12 (0.11, 0.14) | |
DALYs | 1786127 (1768200, 1804055) | 1776155 (1758323, 1793986) |
Difference in DALYs compared to KP | −9973 (−13064, −6882) | |
Net DALYs (DALYs + Costs/$500) | 2099035 (2076774, 2121295) | 2085317 (2062869, 2107766) |
Difference in Net DALYs | −13717 (−17316, −10119) |
